Comparison
5-Amino-1MQ vs AICAR
Both are fat loss, so the meaningful differences are in kinetics, evidence and regulatory status.
On published evidence alone, AICAR is the better documented of the two (clinical trials). That is a statement about the state of the literature, not a recommendation.
| 5-Amino-1MQ | AICAR | |
|---|---|---|
| Class | Fat loss | Fat loss |
| Evidence | Animal models only | Clinical trials |
| Human trials | None published | ~12 |
| Half-life | ~4-6 hours | ~30 minutes |
| Reported range | 50-150 mg | 50-100 mg |
| Frequency | Once daily | Research protocols vary |
| Routes | Oral | Subcutaneous, Oral |
| FDA approved | No | No |
| Research use only | Yes | Yes |
| Banned in sport | No | Yes |
| Studied for | Adipocyte metabolism research, NAD+ pathway research | Metabolic research, Endurance research, Cardioprotection studies |
| Reported side effects | Insomnia, Nausea, Headache | Elevated uric acid, Headache, Nausea, Hypoglycaemia |
5-Amino-1MQ
5-Amino-1MQ is a quinolinium small molecule that inhibits nicotinamide N-methyltransferase, an enzyme highly expressed in white adipose tissue. Inhibiting NNMT raises intracellular nicotinamide and NAD+ and has been reported to reduce adipocyte size and increase energy expenditure in rodent models. There is no published human trial data. It is listed here because it is sold and discussed as a peptide, which it is not.
AICAR
AICAR is a nucleoside that is phosphorylated intracellularly to ZMP, an AMP analog that allosterically activates AMP-activated protein kinase. AMPK activation shifts cells toward catabolism: increased glucose uptake, fatty acid oxidation and mitochondrial biogenesis. Rodent studies showing improved endurance without training drove the exercise-mimetic framing and its early prohibition in sport. Human evidence for body composition effects is weak, and its poor oral bioavailability is a substantial practical limitation.
5-Amino-1MQ vs AICAR: common questions
What is the difference between 5-Amino-1MQ and AICAR?
Both are fat loss. 5-Amino-1MQ: A small-molecule NNMT inhibitor studied for adipocyte metabolism. Not a peptide, despite how it is sold. AICAR: An AMPK activator nicknamed exercise in a pill, and one of the earliest compounds added to WADA banned list as a metabolic modulator.
Which has stronger evidence, 5-Amino-1MQ or AICAR?
AICAR has the stronger evidence base (clinical trials, about 12 human studies) compared with 5-Amino-1MQ (animal models only).
Are 5-Amino-1MQ and AICAR FDA approved?
Neither is FDA approved for any indication.
References
Regulatory and primary sources
- FDA: Unapproved drugs and "research use only" products ↗ · regulatory status of non-approved products
- PubChem compound record (CID 65110) ↗ · structure, identifiers, synonyms
- WADA Prohibited List ↗ · current year
- CAS Registry Number 2627-69-2 ↗ · chemical identity
Published literature
- NAD(+) metabolism enzyme NNMT in cancer-associated fibroblasts drives tumor progression and resistance to immunotherapy by modulating macrophages in urothelial bladder cancer.J Immunother Cancer 2024.PubMed 39067875 · doi:10.1136/jitc-2024-009281
- Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice.Sci Rep 2022.PubMed 35013352 · doi:10.1038/s41598-021-03670-5
- Small molecule inhibitor of nicotinamide N-methyltransferase shows anti-proliferative activity in HeLa cells.J Obstet Gynaecol 2021.PubMed 33645410 · doi:10.1080/01443615.2020.1854696
- AMPK: The energy sensor at the crossroads of aging and cancer.Semin Cancer Biol 2024.PubMed 39197808 · doi:10.1016/j.semcancer.2024.08.002
- Autophagy in the physiological endometrium and cancer.Autophagy 2021.PubMed 32401642 · doi:10.1080/15548627.2020.1752548
- Running-Induced Systemic Cathepsin B Secretion Is Associated with Memory Function.Cell Metab 2016.PubMed 27345423 · doi:10.1016/j.cmet.2016.05.025
- Modulating Mitophagy in Mitochondrial Disease.Curr Med Chem 2018.PubMed 28618992 · doi:10.2174/0929867324666170616101741
- Beyond AICA riboside: in search of new specific AMP-activated protein kinase activators.IUBMB Life 2009.PubMed 18798311 · doi:10.1002/iub.135
- Targeting AMP-activated protein kinase in sepsis.Front Endocrinol (Lausanne) 2024.PubMed 39469575 · doi:10.3389/fendo.2024.1452993
- AICA-riboside (acadesine), an activator of AMP-activated protein kinase with potential for application in hematologic malignancies.Expert Opin Investig Drugs 2010.PubMed 20367195 · doi:10.1517/13543781003703694
- Caloric restriction and exercise "mimetics'': Ready for prime time?.Pharmacol Res 2016.PubMed 26658171 · doi:10.1016/j.phrs.2015.11.009
Literature retrieved from PubMed on October 16, 2026, favouring human studies and reviews. Numbered markers in the text show which paper supports which statement; uncited entries are background reading.